Abstract:Hepatic carboxylesterase 1 (CES1) metabolizes numerous prodrugs into active ingredients or direct-acting drugs into inactive metabolites. We aimed to develop a semi-physiologically based pharmacokinetic (semi-PBPK) model to simultaneously predict the pharmacokinetics of CES1 substrates and their active metabolites in liver cirrhosis (LC) patients. Six prodrugs (enalapril, benazepril, cilazapril, temocapril, perindopril and oseltamivir) and three direct-acting drugs (flumazenil, pethidine and remimazolam) were selected. Parameters such as organ blood flows, plasma-binding protein concentrations, functional liver volume, hepatic enzymatic activity, glomerular filtration rate (GFR) and gastrointestinal transit rate were integrated into the simulation. The pharmacokinetic profiles of these drugs and their active metabolites were simulated for 1000 virtual individuals. The developed semi-PBPK model, after validation in healthy individuals, was extrapolated to LC patients. Most of the observations fell within the 5th and 95th percentiles of simulations from 1000 virtual patients. The estimated AUC and Cmax were within 0.5–2-fold of the observed values. The sensitivity analysis showed that the decreased plasma exposure of active metabolites due to the decreased CES1 was partly attenuated by the decreased GFR. Conclusion: The developed PBPK model successfully predicted the pharmacokinetics of CES1 substrates and their metabolites in healthy individuals and LC patients, facilitating tailored dosing of CES1 substrates in LC patients.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to simultaneously predict the pharmacokinetics of CES1 - metabolized drugs and their metabolites in patients with liver cirrhosis. Specifically, the study aims to develop a semi - physiologically - based pharmacokinetic (semi - PBPK) model to simulate and predict the pharmacokinetic characteristics of CES1 - substrate drugs and their active metabolites in patients with liver cirrhosis. By integrating the effects of liver cirrhosis on liver CES1 activity, liver and kidney function, gastrointestinal transit rate, and blood flow in relevant organs, this model can more accurately predict the pharmacokinetic behavior of drugs in patients with liver cirrhosis, thereby providing a scientific basis for the rational use of drugs in these patients. ### Main research contents: 1. **Background and significance**: - Liver cirrhosis (LC) is a common disease that can lead to impaired liver function and affect a series of physiological parameters, such as functional liver volume, hepatic artery blood flow, portal vein blood flow, glomerular filtration rate (GFR), α - acid glycoprotein, albumin content, drug - metabolizing enzymes, and transporters. - These changes may directly affect the pharmacokinetics of drugs, so it is necessary to adjust the drug dosage in patients with liver cirrhosis. - Physiologically - based pharmacokinetic (PBPK) modeling techniques are considered an ideal method for predicting the pharmacokinetics of drugs in patients with liver cirrhosis. 2. **Research methods**: - A semi - PBPK model was developed, which includes the stomach, intestinal wall, intestinal lumen, portal vein, liver, kidney, and systemic compartments, and is connected through the blood circulation system. - Model parameters include organ blood flow, plasma - binding protein concentration, functional liver volume, liver enzyme activity, GFR, and gastrointestinal transit rate. - Six prodrugs (enalapril, benazepril, cilazapril, temocapril, perindopril, and oseltamivir) and three directly - acting drugs (flumazenil, pethidine, and remimazolam) were selected as research objects. - The model was first validated in healthy individuals and then extended to patients with liver cirrhosis. 3. **Results and conclusions**: - The developed semi - PBPK model successfully predicted the pharmacokinetics of CES1 - substrate drugs and their metabolites in healthy individuals and patients with liver cirrhosis. - Simulation results showed that most of the observed values fell between the 5% and 95% percentiles of 1,000 virtual patients, and the estimated AUC and Cmax were within 0.5 to 2 times the observed values. - Sensitivity analysis indicated that the decrease in GFR partially offset the decrease in plasma exposure of active metabolites caused by the decrease in CES1 activity. ### Summary: This study successfully predicted the pharmacokinetics of CES1 - metabolized drugs and their metabolites in patients with liver cirrhosis by developing and validating a semi - PBPK model, providing a scientific basis for personalized drug use in these patients.

Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects

Application of Ivive and Pbpk Modeling in Prospective Prediction of Clinical Pharmacokinetics: Strategy and Approach During the Drug Discovery Phase with Four Case Studies

Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes

Physiologically Based Pharmacokinetic Modeling to Predict the Impact of Liver Cirrhosis on Glucuronidation via UGT1A4 and UGT2B7/2B4-A Case Study with Midazolam

Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling

Model-Based Dose Selection of a Sphingosine-1-Phosphate Modulator, Etrasimod, in Patients with Various Degrees of Hepatic Impairment

PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters

IDDF2024-ABS-0027 the Prognostic Value of Serum Metabolites in Predicting Hepatic Decompensation among Patients with Cirrhosis

Prediction of Hepatic Plasma Clearance in Vivo from Gel-Entrapped Rat and Human Hepatocytes.

Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates

Development of a Virtual Chinese Pediatric Population Physiological Model Targeting Specific Metabolism and Kidney Elimination Pathways

Simulation of the Pharmacokinetics of Bisoprolol in Healthy Adults and Patients with Impaired Renal Function Using Whole-Body Physiologically Based Pharmacokinetic Modeling

Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators

Interspecies Brain PBPK Modeling Platform to Predict Passive Transport through the Blood–Brain Barrier and Assess Target Site Disposition

Effect of protein binding on the pharmacokinetics of the six substrates in the Basel phenotyping cocktail in healthy subjects and patients with liver cirrhosis

From hazard to risk prioritization: a case study to predict drug-induced cholestasis using physiologically based kinetic modeling

Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach

Advancing Estimation of Hepatobiliary Clearances in Physiologically Based Pharmacokinetic Models of Rosuvastatin Using Human Hepatic Concentrations

Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model

Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling

[Prediction of the Pharmacokinetic Drug-Drug Interaction of Pravastatin and Pitavastatin with Cyclosporine by a Digital Liver Model Based on Metabolism and Transporter].